Healthcare Investing in 2026: iShares Global Healthcare ETF Outperforms Invesco Health Care ETF

iShares Global Healthcare ETF (IXJ) is highlighted versus Invesco S&P 500 Equal Weight Health Care ETF (RSPH) as offering a higher dividend yield of 1.50% vs 0.70% and lower risk (5-year max drawdown of -18.1% vs -22%). IXJ also shows stronger 5-year total return growth of $1,257 vs $1,177, alongside higher liquidity ($4.1B AUM vs $734.1M) while keeping the same 0.40% expense ratio. The article frames IXJ’s market-cap/global exposure and concentration in top names (e.g., Eli Lilly 10.6%) as a trade-off versus RSPH’s equal-weight quarterly rebalancing that aims to smooth volatility.

Analysis

This is not a healthcare-fundamentals call; it is a factor call on concentration, liquidity, and rebalance behavior. The market tends to pay up for defensives that can compound cash flow without drama, so a low-vol, high-yield vehicle like IXJ should keep attracting allocator demand if the tape remains risk-averse. The real winners are the mega-cap cash generators inside the basket; the hidden losers are the smaller, higher-turnover names that get forced into equal-weight products regardless of business quality.

RSPH’s quarterly rebalance is the important second-order effect: it systematically trims recent winners and adds to laggards, which helps only if healthcare breadth broadens. That makes it more sensitive to a genuine regime shift in rates or risk appetite, especially for higher-beta subsectors like biotech and life sciences tools. If the market stays selective, the fund’s design becomes a drag rather than a feature, because it redistributes exposure away from the strongest balance sheets and toward names with more event risk.

The contrarian miss is that the debate is less about "U.S. vs global healthcare" and more about whether the sector stays a haven or rotates into a broader beta trade. IXJ’s liquidity and yield can create a self-reinforcing institutional preference, but concentration risk cuts both ways: one large-cap pharma stumble would matter more there than in RSPH. What would falsify the edge is a sustained relative breakout in equal-weight healthcare over the next 1-2 quarters, especially if it coincides with lower real yields and a rebound in biotech/tools sentiment.

Key Decisions for Investors

• Prefer IXJ over RSPH for core healthcare exposure over the next 3-6 months; it is the cleaner defensive vehicle. Use pullbacks to add, and treat a 3-4% relative underperformance versus RSPH over a quarter as a thesis warning.
• For a tactical relative-value trade, go long IXJ / short RSPH in a small size. The edge comes from lower vol, higher income, and less rebalance drag, so the reward is modest but cleaner than a directional sector bet.
• Avoid chasing the equal-weight basket unless you want a rotation expression. RSPH is more interesting only if real yields roll over and biotech/tools breadth improves; otherwise its quarterly forced buying of laggards is a structural headwind.
• Within the sector, favor defensive cash-flow names like JNJ and ABBV on weakness versus the more event-driven names embedded in equal-weight vehicles. The trade breaks if either company issues a guidance reset or healthcare leadership broadens materially in the next earnings cycle.